Zetagen
Our Company
The Science
Therapies
Oncology
OverviewZetaMet™ (Zeta-BC-003)ZetaMet-P™ (Zeta-PC-004)ZetaMAST™ (Zeta-MBC-005)ZetaBase®
Musculoskeletal
Overview
News
Press Releases
Publications
Walk With You
Research
Overview
Regulatory Status
Clinical Trials
Contact Us

News

Keep Up to date with our latest news and press releases

Zetagen Therapeutics, Inc. Awarded $225,000 USD Grant from NIAMS for Phase I Study of Novel Osteoinductive Lumbar Fusion Implant for Small Molecule-Based

September 11, 2019, (Syracuse, New York) - Zetagen Therapeutics, Inc., a private, US-based biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, announced today its award of $225,000 USD from the National Institute of Arthritis and Musculoskeletal and Skin Diseases
Read More

Zetagen Therapeutics, Inc. Receives Patent for Regulation of Bone Growth and Bone Degradation Using Small-Molecule

April 23, 2019 – (Syracuse, New York) - Zetagen Therapeutics, Inc., a private, US-based biotechnology company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, announced today that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 102656437 to the Company.
Read More

Zetagen Therapeutics, Inc. Receives Patents for Methods in Stimulating Bone Growth Using Small-Molecule

February 19, 2019– (Syracuse, New York) - Zetagen Therapeutics, Inc., a private, US-based biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and orthopedic interventions, announced today that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 10208306 and the South African Patent Office issued PCT. 201700029 to the Company.
Read More

Zetagen Therapeutics, Inc. Awarded $300,000 USD Grant from the National Cancer Institute (NCI) for Phase I Study of Novel, Adjuvant Implant for Post-Metastatic Skeletal Lesions

September 5, 2018– (Syracuse, New York) - Therapeutics, Inc., a private, US-based biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, announced today its award of a $300,000 (USD) grant from the National Cancer Institute of the National Institutes of Health (NIH).
Read More
1 2 3
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.
OK